Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$425.0M
34M shares
52-week range
$9.85 – $16.76
41% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.59%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.4M | $17.4M | $97.0K | $59.0K | $73.0K | $75.0K | $0 | $0 |
| Cost of revenue | $243.9K | $304.1K | −$185.0K | $123.0K | $9.0K | $0 | $343.0K | $0 |
| Gross profit | −$39.5K | $7.8M | $282.0K | −$64.0K | $64.0K | $75.0K | −$343.0K | −$396.0K |
| Gross margin | -0.9% | 44.5% | 290.7% | -108.5% | 87.7% | 100.0% | — | — |
| R&D | $3.7M | $3.2M | $3.0M | $7.0M | $11.3M | $12.8M | $15.6M | $18.3M |
| Operating income | −$8.7M | $1.8M | −$8.3M | −$13.6M | −$17.9M | −$19.1M | −$22.5M | −$41.8M |
| EBITDA | −$6.3M | $1.9M | −$7.9M | −$13.5M | −$17.8M | −$18.7M | −$22.1M | −$41.4M |
| Net income | −$6.3M | $1.8M | −$8.3M | −$13.9M | −$18.2M | −$19.6M | −$21.8M | −$37.9M |
| Net margin | -143.0% | 10.5% | -8529.9% | -23528.8% | -24942.5% | -26082.7% | — | — |
| EPS (diluted) | -103.60 | 28.45 | -8.10 | -27.27 | -19.31 | -14.12 | -2.68 | -1.05 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $25M | $-1.02 | $-1.10–$-0.94 | 4 |
| 2027 | $27M | $-0.97 | $-1.05–$-0.88 | 2 |
| 2028 | $71M | $-1.48 | $-1.48–$-1.48 | 1 |
| 2029 | $131M | $-2.23 | $-2.23–$-2.23 | 1 |
Forward consensus · source: Financial Modeling Prep
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
www.benitec.comNo one on the platform currently holds BNTC.
No tracked institution reports a position in BNTC as of their last filing.
| Execution date | Ratio |
|---|---|
| 2023-07-26 | 1-for-17reverse |
No one on the platform has traded BNTC yet.
| $337M |
| — |
| NGNENeurogene Inc. | $32.28 | +0.78% | $510M | — |
| OCGNOcugen, Inc. | $1.67 | +11.33% | $565M | — |
Source: Financial Modeling Prep · peers by sector/industry
Trading at NaN× sales vs its 528.6× historical median P/S.
Fair value ≈ $0.00 · price $12.70 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$BNTC Share Price: $10.40 Contract Selected: Oct 16, 2026 $10 Calls Buy Zone: $0.42 – $0.53 Target Zone: $0.71 – $0.87 Potential Upside: 57% ROI Time to Expiration: 127 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗$BNTC released its fiscal quarter ended March 31, 2026 results and operational update.
View on StockTwits ↗$BNTC (+2.2% pre) Benitec Biopharma to present BB-301 clinical data at gene therapy meeting https://ooc.bz/l/100204
View on StockTwits ↗$BNTC Spec biotech that tends to react sharply to volume shifts. Recently showing stabilization after volatility. If it breaks resistance, fast momentum entries usually follow.
View on StockTwits ↗$BNTC (+5.8% pre) Benitec reports positive interim results for OPMD gene therapy BB-301 https://ooc.bz/l/95947
View on StockTwits ↗$BNTC 07:13 on Mar. 09 2026 Benitec Biopharma Announced Promising Interim Clinical Results From The BB-301 Phase 1b/2a First-in-human Study (NCT06185673) Evaluating Low Dose And High Dose BB-301 Treatment For Oculopharyngeal Muscular Dystrophy With Moderate Dysphagia #tradeideas
View on StockTwits ↗$BNTC Current Stock Price: $10.47 Contracts to trade: $12.5 BNTC Feb 20 2026 Call Entry: $0.72 Exit: $1.36 ROI: 88% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
View on StockTwits ↗$BNTC Immuno-oncology biotech with early-stage upside and high uncertainty.
View on StockTwits ↗$BNTC Benitec Biopharma; gene therapy biotech; early-stage, high-risk; binary catalyst.
View on StockTwits ↗$BNTC Share Price: $12.68 Contract Selected: Jul 17, 2026 $12.5 Calls Buy Zone: $0.42 – $0.53 Target Zone: $0.68 – $0.83 Potential Upside: 50% ROI Time to Expiration: 175 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.